Scientists Just Unlocked an Endless Army of Cancer-Fighting Cells

Key Points:

• Researchers at the University of Southern California have developed a method to genetically engineer macrophage progenitor cells, known as granulocyte-monocyte progenitors (GMPs), which can self-renew and produce functional immune cells, offering a scalable source for cancer immunotherapies.
• Unlike traditional CAR-T therapies that modify T cells and work best against blood cancers, engineered GMPs can generate macrophages that effectively target both blood and solid tumors, overcoming previous challenges in growing and storing macrophages for treatment.
• In mouse models, lab-grown GMPs produced a continuous supply of macrophages and other immune cells, spreading throughout the body and inhibiting cancer progression in blood and solid tumors, demonstrating potential for broad therapeutic applications.
• This approach suggests that targeting progenitor cells at the right developmental stage may enhance the effectiveness of immunotherapies, potentially leading to improved treatments for cancer and other diseases beyond current CAR-T methods.
• The study, highlighting the promise of engineered macrophage progenitors in cancer treatment, was published in the journal Cell and opens new avenues for research and clinical translation in immunotherapy.